Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Gastroenterology ; 146(2): 392-400.e3, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24512909

RESUMO

BACKGROUND & AIMS: The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for ulcerative colitis (UC) have not been evaluated previously. METHODS: This randomized, double-blind trial evaluated the efficacy and safety of 16 weeks of treatment with infliximab monotherapy, azathioprine monotherapy, or the 2 drugs combined in tumor necrosis factor-a antagonist-naive adults with moderate to severe UC. Patients were assigned randomly to receive intravenous infusions of infliximab 5 mg/kg at weeks 0, 2, 6, and 14 plus daily oral placebo capsules; oral azathioprine 2.5 mg/kg daily plus placebo infusions on the infliximab schedule; or combination therapy with the 2 drugs. Corticosteroid-free clinical remission (primary end point, week 16) was evaluated at weeks 8 and 16. The study was terminated before the enrollment target was reached. RESULTS: A total of 239 patients were included in efficacy analyses. Baseline characteristics were similar between treatment groups. Corticosteroid-free remission at week 16 was achieved by 39.7% (31 of 78) of patients receiving infliximab/azathioprine,compared with 22.1% (17 of 77) receiving infliximab alone(P =.017) and 23.7% (18 of 76) receiving azathioprine alone(P =.032). Mucosal healing at week 16 occurred in 62.8% (49 of 78) of patients receiving infliximab/azathioprine, compared with 54.6% (42 of 77) receiving infliximab (P = .295) and 36.8% (28 of 76) receiving azathioprine (P =.001). Serious infections occurred in 2 patients (1 patient receiving infliximab,and 1 patient receiving azathioprine). CONCLUSIONS: Anti­tumor necrosis factor-a­naive patients with moderate to severe UC treated with infliximab plus azathioprine were more likely to achieve corticosteroid-free remission at 16 weeks than those receiving either monotherapy. Combination therapy led to significantly better mucosal healing than azathioprine monotherapy. ClinicalTrials.gov number, NCT00537316.


Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Azatioprina/uso terapêutico , Colite Ulcerativa/tratamento farmacológico , Imunossupressores/uso terapêutico , Quimioterapia de Indução/métodos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Método Duplo-Cego , Esquema de Medicação , Quimioterapia Combinada , Feminino , Humanos , Infliximab , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , Índice de Gravidade de Doença , Resultado do Tratamento , Adulto Jovem
2.
J Crohns Colitis ; 2020 Jul 29.
Artigo em Inglês | MEDLINE | ID: mdl-32722760

RESUMO

BACKGROUND: The understanding the Impact of ulcerative COlitis aNd Its assoCiated disease burden on patients study [ICONIC] was a 2-year, global, prospective, observational study evaluating the cumulative burden of ulcerative colitis [UC] using the Pictorial Representation of Illness and Self-Measure [PRISM] tool that is validated to measure suffering, but not previously used in UC. METHODS: ICONIC enrolled unselected outpatient clinic attenders with recent-onset UC. Patient- and physician-reported outcomes including PRISM, the Short Inflammatory Bowel Disease Questionnaire [SIBDQ], the Patient Health Questionnaire [PHQ-9], and the Simple Clinical Colitis Activity Indexes [patient: P-SCCAI; physician: SCCAI] were collected at baseline and follow-up visits every 6 months. Correlations between these measures were assessed using Spearman's rank correlation coefficient. RESULTS: Overall, 1804 evaluable patients had ≥1 follow-up visit. Over 24 months, mean [SD] disease severity measured by P-SCCAI/SCCAI reduced significantly from 4.2 [3.6]/3.0 [3.0] to 2.4 [2.7]/1.3 [2.1] [p<0.0001]. Patient-/physician-assessed suffering, quantified by PRISM, reduced significantly over 24 months [p<0.0001]. SCCAI/P-SCCAI, and patient-/physician-assessed PRISM, showed strong pairwise correlations [rho ≥0.60, p<0.0001], although physicians consistently underestimated these disease severity and suffering measures compared with patients. Patient-assessed PRISM moderately correlated with other outcome measures, including SIBDQ, PHQ-9, P-SCCAI, and SCCAI (rho = ≤-0.38 [negative correlations] or ≥0.50 [positive correlations], p<0.0001). CONCLUSION: Over 2 years, disease burden and suffering, quantified by PRISM, improved in patients with relatively early UC. Physicians underestimated burden and suffering compared with patients. PRISM correlated with other measures of illness perception in patients with UC, supporting its use as an endpoint reflecting patient suffering.

3.
Rev. colomb. gastroenterol ; 16(1): 8-18, mar. 2001. ilus, tab, graf
Artigo em Espanhol | LILACS | ID: lil-346463

RESUMO

La colitis isquémica (CI) es la forma más común de injuria isquémica al tracto gastrointestinal, dada por una insuficiencia circulatoria del colon lo cual causa varios grados de necrosis tisular local, con o sin repercuciones sistémicas sin poder predecir el curso final de la enfermedad. Con el objeto de identificar los grupos de población susceptibles de sufrir esta patología, sus patrones de presentacion y sus complicaciones. Se realizó una revisión retrospectiva de quince casos (8 hombres, 7 mujeres), diagnosticados como CI por el Servicio de Cirugía y Endoscopia Colorrectal (SCECR) del Hospital Militar Central en un periodo comprendido entre enero de 1989 y enero del 2000. Se encontró que la hipertensión arterial y otras enfermedades cardiovasculares son los antecedentes patológicos asociados más frecuentes (73 por ciento). El tiempo transcurrido entre el inicio de los síntomas y el diagnóstico fue de 10,6 días (1-30). El examen de elección para el diagnóstico es la colonoscopia y el encontrar lesiones ulceradas circunferenciales son signos ominosos


Assuntos
Colite Isquêmica/diagnóstico , Colite Isquêmica/etiologia , Colite Isquêmica/fisiopatologia , Colite Isquêmica/patologia , Colite Isquêmica/terapia
4.
Rev. colomb. gastroenterol ; 17(2): 88-98, jun. 2002. tab, graf
Artigo em Espanhol | LILACS | ID: lil-346411

RESUMO

Las preparaciones de colon para la colonoscopia se han regido entre la capacidad de limpieza de éstas y la aceptabilidad por parte del paciente. El método ideal de preparación de colon debe proveer una limpieza eficaz, rápida y segura sin comodidad para el paciente. Debe ser un método sencillo y costo-efectivo para uso tanto en pacientes ambulatorios como hospitalizados. Cien pacientes fueron remitidos al Servicio de Cirugía y Endoscopio del Hospital Militar Central para colonoscopia diagnóstica, donde se les preparó el colon con un método a base de fosfato sódico, fueron aleatoriamente divididos en dos grupos: el grupo A recibió el esquema tradicional y el grupo B recibió la solución diluida. Fueron comparadas la efectividad de limpieza, la seguridad y la aceptabilidad entre los dos esquemas. La distribución de las muestras fue homogénea y sin diferencias estadísticas en cuanto a edad y sexo. Los pacientes del grupo A se anejaron de distensión abdominal (52 por ciento vs. 28 por ciento, p = 0.14), irritación anal (60 por ciento vs. 36 por ciento, p = 0.016 ) y escalofríos (60 por ciento vs. 38 por ciento, p = 0.028). En el grupo B, los pacientes presentaron más debilidad (42 por ciento vs. 22 por ciento, p = 0.032). Noventa y seis por ciento de los pacientes en el grupo B ingirieron el 100 por ciento del volumen total de la preparación frente al 90 por ciento en el grupo A (p = 0.24). Ochenta y ocho por ciento de los pacientes en el grupo B volverían a tomarse la preparación frente a 78 por ciento en el grupo A (p = 0.183). Los endoscopistas encontraron el colon limpio en el 72 por ciento del grupo B vs. el 22 por ciento en el grupo A (p = 0.000) y calificaron la preparación del colon como excelente en el 70 por ciento del grupo S frente a 22 por ciento para el grupo A (p = 0.000). Aunque hubo alteraciones hidroelectrolíticas entre ambos grupos, todas fueron subclínicas; se encontró que el grupo B tuvo mayor aceptabilidad, mejor tolerancia y mayor efectividad de limpieza especialmente a nivel del colon derecho, que el grupo A


Assuntos
Colonoscopia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA